Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Illumina Inc (ILMN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,516,920
  • Shares Outstanding, K 146,000
  • Annual Sales, $ 2,398 M
  • Annual Income, $ 462,650 K
  • 36-Month Beta 0.74
  • Price/Sales 12.69
  • Price/Cash Flow 45.45
  • Price/Book 10.66

Price Performance

See More
Period Period Low Period High Performance
1-Month
198.21 +5.45%
on 10/25/17
214.50 -2.55%
on 10/23/17
+2.54 (+1.23%)
since 10/17/17
3-Month
189.15 +10.50%
on 08/18/17
214.50 -2.55%
on 10/23/17
+17.82 (+9.32%)
since 08/17/17
52-Week
119.37 +75.10%
on 12/07/16
214.50 -2.55%
on 10/23/17
+74.93 (+55.88%)
since 11/17/16

Most Recent Stories

More News
Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx

Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.

PETS : 38.67 (-1.98%)
ILMN : 209.02 (+0.24%)
MYGN : 32.88 (-1.59%)
ALGN : 253.89 (-0.40%)
Illumina Grows Clinical IVD Portfolio with Introduction of NextSeq(TM) 550Dx System and Expanded Use of MiSeq(TM)Dx System

Illumina, Inc. (NASDAQ: ILMN) announced today the introduction of its NextSeq(TM) 550Dx instrument, the company's second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system....

ILMN : 209.02 (+0.24%)
Illumina Names Gary S. Guthart, Ph.D., to its Board of Directors, Adding Decades of Leadership Experience in Healthcare

Illumina, Inc. (NASDAQ: ILMN) announced today that Gary S. Guthart will join the company's Board of Directors on December 1, 2017. Dr. Guthart is President and Chief Executive Officer of...

ILMN : 209.02 (+0.24%)
ISRG : 392.48 (-0.34%)
Earnings Review and Free Research Report: Illumina's Revenue Advanced 18%; EPS Surged 28%

Research Desk Line-up: Sarepta Therapeutics Post Earnings Coverage

SRPT : 56.11 (+1.94%)
ILMN : 209.02 (+0.24%)
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

EXAS : 58.87 (+0.63%)
ILMN : 209.02 (+0.24%)
EXEL : 26.38 (+2.13%)
SHPG : 147.37 (+1.89%)
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3

Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.

PETS : 38.67 (-1.98%)
OMCL : 48.25 (+0.63%)
ILMN : 209.02 (+0.24%)
ISRG : 392.48 (-0.34%)
Corporate News Blog - US FDA Green Signals Clinical Investigation of Biohaven Pharma's Trigriluzole For Treatment Of OCD

Research Desk Line-up: Illumina Post Earnings Coverage

BHVN : 25.61 (+0.99%)
ILMN : 209.02 (+0.24%)
Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance

Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.

PETS : 38.67 (-1.98%)
ABT : 55.56 (+0.04%)
ILMN : 209.02 (+0.24%)
ISRG : 392.48 (-0.34%)
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2017

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the third quarter of fiscal year 2017.

ILMN : 209.02 (+0.24%)
Illumina, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 24, 2017 / Illumina, Inc. (NASDAQ: ILMN) will be discussing their earnings results in their Q3 Earnings Call to be held on October 24, 2017 at 5:00 PM Eastern Time.

ILMN : 209.02 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company's tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing...

See More

Key Turning Points

2nd Resistance Point 210.91
1st Resistance Point 209.97
Last Price 209.02
1st Support Level 208.08
2nd Support Level 207.13

See More

52-Week High 214.50
Last Price 209.02
Fibonacci 61.8% 178.16
Fibonacci 50% 166.93
Fibonacci 38.2% 155.71
52-Week Low 119.37

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart